Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. regarding potential breaches of fiduciary duties by certain officers and directors of the company [1]. Group 1: Investigation Details - The investigation focuses on whether certain officers and directors of Unicycive Therapeutics breached their fiduciary duties to the company [1]. - Shareholders who purchased Unicycive shares prior to March 29, 2024, and still hold them can seek corporate reforms and the return of funds to the company at no cost [2][4]. Group 2: Allegations of Misconduct - A federal securities fraud class action complaint alleges that Unicycive's officers made false statements regarding the company's readiness to meet FDA manufacturing compliance requirements and overstated the regulatory prospects of the oxylanthanum carbonate new drug application [3]. - The public statements made by the defendants were claimed to be materially false and misleading at all relevant times [3].